--- title: "Weekly Recap | Oncolytics Biotech -11.73%, hitting a one-month low" type: "News" locale: "en" url: "https://longbridge.com/en/news/301470369.md" description: "Oncolytics Biotech (ONCY) fell 11.73% this week to $0.557, while the S&P 500 gained 1.15%, roughly a 12.88 percentage point gap. The stock opened Monday at $0.6362, its weekly high, then drifted lower through the week. Thursday’s drop brought it to $0.5444, and Friday’s intraday low of $0.525 marked a new low for the past month. The shares closed at $0.557 on Friday. Weekly amplitude was 17.48%, and average daily volume came in around 1." datetime: "2026-10-10T07:22:09.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/301470369.md) - [en](https://longbridge.com/en/news/301470369.md) - [zh-HK](https://longbridge.com/zh-HK/news/301470369.md) generator: "portal-rs" --- # Weekly Recap | Oncolytics Biotech -11.73%, hitting a one-month low ## The Week Oncolytics Biotech (ONCY) fell 11.73% this week to $0.557, while the S&P 500 gained 1.15%, roughly a 12.88 percentage point gap. The stock opened Monday at $0.6362, its weekly high, then drifted lower through the week. Thursday’s drop brought it to $0.5444, and Friday’s intraday low of $0.525 marked a new low for the past month. The shares closed at $0.557 on Friday. Weekly amplitude was 17.48%, and average daily volume came in around 1.21m shares, about 50% above the median, showing heavier trading as prices moved down. ## Key Events Two material filings hit the tape on Wednesday, 7 October: a DEF 14A and a DEFA14A, both related to shareholder meeting materials. On the news side, the only item this week was a 6 October piece on cross-border regulatory strategies for healthcare and chip firms, with no company-specific disclosures. Oncolytics itself did not put out product, clinical or financial updates this week. ## Analyst Ratings Seven analysts cover the name: 2 rate it buy, 1 overweight, 1 hold and 1 no-opinion, with no underweight or sell. The stock ranks 224th among 508 names in the biotech space. The consensus rating is buy, and the consensus target sits at $4.17, roughly 648.8% above the current price of $0.557. Targets range from a high of $5.891 to a low of $2.864, pointing to wide disagreement. A separate aggregate shows 2 strong-buy, 3 buy and 1 hold across 6 analysts, still buy-leaning overall. ## The Week Ahead Macro data dominates next week. On 13 October, the US releases the NFIB small business optimism index and existing-home sales at an annual rate. On 14 October, several CPI prints land: headline CPI with a prior of 3.4 and a forecast of 3.7, core CPI with a prior of 2.4 and a forecast of 2.5, and another CPI reading with a prior of 0.4 and a forecast of 0.6. If inflation surprises, biotech valuations could swing. Oncolytics has no disclosed earnings or pipeline events on the calendar yet, so watch whether the shareholder meeting materials lead to further news. ## In Short The shares sold off this week with little fresh company news and closed near the recent low on heavier volume. Offsetting that, analysts still give the stock a buy consensus, with a target well above spot, though the wide target range shows the estimates are anything but aligned. PB and PE are both negative, a sign the company is not yet profitable on paper, while the latest session’s large-lot flow was positive but smaller orders were split. The tension is between a beaten-down tape and a still-positive sell-side view. What matters next is whether inflation data shakes biotech broadly, and whether Oncolytics can deliver its own clinical or corporate catalysts. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [ONCY.US](https://longbridge.com/en/quote/ONCY.US.md) ## Related News & Research - [Oncolytics Showcases Pelareorep Phase 2 mCRC Study Plans](https://longbridge.com/en/news/302435335.md) - [Stocks in Play: Oncolytics Biotech Inc](https://longbridge.com/en/news/301743192.md) - [Oncolytics Biotech says new pelareorep cancer immunotherapy method-of-use patent issues in several countries](https://longbridge.com/en/news/301621348.md) - [EXCLUSIVE-Samsung, SK Hynix upgrading China plants to make more advanced chips, people say](https://longbridge.com/en/news/302503728.md) - [Warren Buffett's Successor, Greg Abel, Just Went Shopping in the Tech Sector Again!](https://longbridge.com/en/news/302535520.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**